Clinical Research Program
The Muhammad Ali Parkinson Center and Movement Disorders Clinic at Barrow Neurological Institute in Phoenix, Arizona is recognized as a center of excellence in the clinical treatment and research of Parkinson's disease and other movement disorders. Clinical research is focused on developing better treatments, slowing disease progression, relieving disease symptoms and controlling motor fluctuations.
Our Goal
We are dedicated to pushing the frontiers of science in the fundamental understanding of Parkinson's disease and other movement disorders such as dystonia, essential tremor and Huntington's disease. As such, we have a team of neurological experts who are committed to providing knowledgeable, thorough and considerate care.
The research staff are members of the Parkinson and Dystonia Study Groups. The Parkinson and Dystonia Study Groups are a consortium of physicians and other healthcare providers from approximately 60 sites across the U.S. and Canada who are dedicated to the research of Parkinson's disease, dystonia and other movement disorders. Our Center is also affiliated with the Benign Essential Blepharospasm Association and the International Essential Tremor Foundation.
The Muhammad Ali Parkinson Center and Movement Disorders Clinic also participates in non-pharmacologic studies. These studies allow researchers to learn more about the effects of Parkinson's disease and other movement disorders on quality of life and motor function as well as on non-motor symptoms.
We are unique in integrating state of the art patient care and counseling with pharmacologic clinical trials and basic research into the cause of movement disorders.
Frequently Asked Questions
What is a Clinical Trial?
A clinical trial is a study of the safety and efficacy of a new drug or other treatment that is designed to answer questions about the drugs while safeguarding the health of the volunteer. A clinical trial may also involve testing of human subjects to aid in a better understanding of underlying disease processes.
Experienced staff conducts these types of studies. The research staff at the Muhammad Ali Parkinson Center have participated in more than 50 phase II, phase III and phase IV studies in Parkinson's disease and other movement disorders
Why Enroll in a Research Clinical Trial?
There are many excellent reasons to participate in a research clinical trial. It allows you access to promising drugs that may not be available commercially for several years. During the course of the trial, you will experience the comprehensive and thorough medical evaluation and attention that research enables. Your research physician is dedicated to better understanding you and your response in a cooperative data gathering mode that is the foundation of medical research.
You will, as a result of the process, learn a great deal about your condition and the range of options that are available to treat your condition. The entire process is of no cost to you and there is the added benefit of contributing individually to a better understanding of movement disorders in general that will benefit others.
Clinical Trials Available
The Muhammad Ali Parkinson Center has a wide variety of leading edge clinical trials. Each will be discussed in turn and will focus on the objectives of the study and the requirements of the participants.
Effects of Coenzyme Q10 on Early Parkinson Disease (QE3)- The primary objective of this study is to compare with placebo the effects of two dosages of CoQ 10 on slowing the progressive impairment of Parkinson disease in early, otherwise treated subjects. Read More...
NPP002- This study is designed to answer the question: will nicotine at doses that do not cause serious side effects show feasibility in the treatment of levodopa-induced dyskinesia in patients with Parkinson Disease. Read More...
ANDANTE- This study will look at the effectiveness of adding an MAO inhibitor (Rasagiline) to a stable dose of a dopamine agonist in subjects with early Parkinson Disease. Read More...
IPX066 vs Conventional CD-LD in Advanced Parkinson Disease- This is a study to evaluate the safety and efficacy of IPX066 (slow release carbidopa-levodopa) in advanced Parkinson Disease. Read More...
Tigan with Apokyn Use- the purposes of this study are to determine the safety and efficacy of Tigan to control nausea/vomiting experienced during Apokyn initiation and treatment. Read More...
Contact Us
If you are interested in learning more about any of our research trials, please call our clinical trials office at 602-406-6259 or email us at info@maprc.com. | 
